Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 8, 2009European Journal Of Haematology

Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune‐mediated severe ADAMTS13‐deficiency: a report of four cases and a systematic review of the literature

View Full Paper
Ask AI
Bookmark
Share

Authors

MEMischelle A. Elliott
John A. Heit
John A. HeitVascular MedicineRPRajiv K. PruthiMayo Clinic

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Elliott et al. (2009) studied this question.

synapsesocial.com/papers/6aa53693bc2c7db7488e357ahttps://doi.org/10.1111/j.1600-0609.2009.01292.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Successful repeat therapy with rituximab for relapsed thrombotic thrombocytopenic purpura2007 · 20 citations
  2. 2Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS‐132006 · 268 citations
  3. 3Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab2002 · 192 citations
  4. 4Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic Purpura1991 · 1,940 citations
  5. 5The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders2006 · 63 citations